Disease Domain | Count |
---|---|
Immune System Diseases | 2 |
Neoplasms | 1 |
Infectious Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Autologous CAR-T | 1 |
Mesenchymal stem cell therapy | 1 |
Top 5 Target | Count |
---|---|
CD19(B-lymphocyte antigen CD19) | 1 |
β-lactamase(Beta Lactamase) | 1 |
Target- |
Mechanism- |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD19 modulators |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism β-lactamase inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Mar 2026 |
Sponsor / Collaborator |
Start Date01 Jun 2025 |
Sponsor / Collaborator |
Start Date09 Apr 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
TranspoCART19(Instituto de Investigación Biomédica de Salamanca) ( CD19 ) | B-cell lymphoma refractory More | Phase 2 Clinical |
Allogenic adult adipose tissue-derived mesenchymal stem cells(IBSAL) | Dry Eye Syndromes More | Phase 2 |
6-Halopyridylmethylidene bromopyridyl 2 ( β-lactamase ) | Pseudomonas aeruginosa infection More | Preclinical |